Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782340 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
A Phase 3 study, sponsored by Chelsea Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 263
- Enrollment target
NCT00782340 is a Phase 3 study that has completed, run by Chelsea Therapeutics. The registered enrollment target is 263 participants.
The verdict
NCT00782340, a Phase 3 study, has completed, sponsored by Chelsea Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 263 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.
Interventions
- DRUG Placebo
- DRUG Droxidopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782340
The ClinicalTrials.gov registry entry for NCT00782340 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chelsea Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00782340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782340 about?
NCT00782340 is a clinical study titled "A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa". The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.
What is the current status of trial NCT00782340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 263 participants. The study started on 2008-09. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00782340?
The interventions under investigation include: Placebo (DRUG), Droxidopa (DRUG).
Who is sponsoring clinical trial NCT00782340?
This trial is sponsored by Chelsea Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.